Buy or sell Sano stock pre IPO via an EquityZen fund
Sano is developing a low cost, Point of Care diagnostic platform to early detect and intervene in at least 6 different diseases.
About Sano Stock
Sano is developing a low cost, Point of Care diagnostic platform to early detect and intervene in at least 6 different diseases affecting human and vet populations. Their first focus is human chronic wounds, such as diabetic foot ulcers and venous leg ulcers, personalizing treatment to promote faster healing and avoid over $3B in treatment costs from trial and error and prolonged chronicity. They have tested their proprietary chemistry, have prototypes designed, and soon will start clinical trials and submit for regulatory clearance. "Low Cost" means that they not only anticipate faster adoption in the developed world, but also that their solution is truly a global solution, not one reserved for wealthy nations alone as obesity, diabetes, and aging population are trends affecting nearly every nation and sharply increase the incidence of chronic wounds.
Chief Scientific Officer
Chief Financial Officer
Business Insider - Feb, 3 2018
The Verge - Jan, 5 2018